Apply for the NCAT/SBIR/STTR Funding by Sept 5

The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health invites small businesses to apply for funding through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) 2018 Omnibus Grant Solicitations:

NCATS encourages applications that address a range of focus areas relevant to any stage of translation, from target validation through pre-clinical and clinical evaluation, to intervention implementation and dissemination, including:

  • Drug Discovery and Development
  • Biomedical, Clinical and Health Research Informatics
  • Clinical, Dissemination and Implementation Research

The deadline to apply is Sept. 5, 2018, 5:00 p.m. local time.

Benefits of Applying:

  • Funding is stable, predictable and not a loan
  • Capital is non-dilutive
  • Small businesses retain intellectual property rights
  • NIH’s rigorous peer-review provides recognition, validation and visibility to early-stage companies and can help attract more funding or other support (e.g., VC, strategic partners)

Guide for Applying:

Follow the SBIR/STTR Application Guide to ensure proper grant application content and format. Applicants may submit their application using ASSIST or the Grants.gov Workspace.
Questions? NCATS encourages applicants to email NCATS-SBIRSTTR@mail.nih.gov to discuss potential project ideas and related questions. Visit our website to learn more about additional funding opportunities and resources, as well as eligibility requirements and research priorities.

Connect with us! Like us on Facebook and follow us on Twitter. Use #NCATSsbir and join the online conversation.

 

NCATS’ SBIR and STTR programs are engines of innovation for developing and commercializing tools, technologies and intervention platforms to support the creation of new therapeutics and diagnostics. SBIR and STTR are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.